Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Dimerix Ltd's valuation more than doubles after Kathy Harrison delivers results

Dimerix's valuation has doubled in the past month.
Dimerix Ltd's valuation more than doubles after Kathy Harrison delivers results
Kathy Harrison, chief executive officer, recently presenting at Proactive's CEO Sessions

Dimerix Ltd's (ASX:DXB) shares continue to rally on the back of positive results from its Phase 2a Trial of DMX-200 in Chronic Kidney Disease (CKD).

At the open of trade Dimerix is changing hands at $0.015 per share, which is double the valuation a month ago before the results.

Why the change in valuation

The importance of Dimerix's Phase 2a results is that the trial meets the primary safety endpoint and demonstrates encouraging efficacy in a clinically meaningful number of patients.

- 25% of patients achieved a greater than 50% reduction in proteinuria, beyond that achieved with the highest dosage of current standard of care therapy; and

- 45% of patients granted ability to continue ongoing treatment under Special Access Scheme upon recommendation of their advising physician, confirming confidence in the treatment.

The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program.

Given this is a “hard to treat” patient group, Dimerix now have a very strong indication that the treatment is having a significant impact in slowing the progression of CKD.

Market for Chronic Kidney Disease

CKD is a growing global health problem affecting over 13% of Australians, and 14% of Americans.

The increase in suffers is due to large number of people living with obesity and diabetes.

The problem is that damaged kidneys “leak” proteins into the urine, known as proteinuria.

This compounds itself which leads to damage of the kidneys.

Next steps

Preparations are well underway to design the Phase 2b efficacy study for DMX-200.

Using the inputs from this Phase 2a study, Dimerix will now finalise design of the patient inclusion criteria, dosing and timetable, which is expected to start by the end of 2017.

View full DXB profile View Profile

Dimerix Ltd Timeline

Newswire
September 10 2014

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use